Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys

@article{Nagai2020DeschloroclozapineAP,
  title={Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys},
  author={Yuji Nagai and Naohisa Miyakawa and Hiroyuki Takuwa and Yukiko Hori and Kei Oyama and Bin Ji and Manami Takahashi and Xi-Ping Huang and Samuel T. Slocum and Jeffrey F. DiBerto and Yan Xiong and Takuya Urushihata and Toshiyuki Hirabayashi and Atsushi Fujimoto and Koki Mimura and Justin G. English and Jing Liu and Ken-ichi Inoue and Katsushi Kumata and Chie Seki and Maiko Ono and Masafumi Shimojo and Ming-Rong Zhang and Yutaka Tomita and Jin Nakahara and Tetsuya Suhara and Masahiko Takada and Makoto Higuchi and Jian Jin and Bryan L. Roth and Takafumi Minamimoto},
  journal={Nature Neuroscience},
  year={2020},
  pages={1-11}
}
The chemogenetic technology designer receptors exclusively activated by designer drugs (DREADDs) afford remotely reversible control of cellular signaling, neuronal activity and behavior. Although the combination of muscarinic-based DREADDs with clozapine- N -oxide (CNO) has been widely used, sluggish kinetics, metabolic liabilities and potential off-target effects of CNO represent areas for improvement. Here, we provide a new high-affinity and selective agonist deschloroclozapine (DCZ) for… 

Figures and Tables from this paper

Behavioral and slice electrophysiological assessment of DREADD ligand, deschloroclozapine (DCZ) in rats
TLDR
The effectiveness of systemic DCZ for DREADD-based chemogenetic manipulations in behavioral and slice electrophysiological applications in rats is examined and evidence that DCZ is a superior alternative to CNO is provided.
Chemogenetic Seizure Control with Clozapine and the Novel Ligand JHU37160 Outperforms the Effects of Levetiracetam in the Intrahippocampal Kainic Acid Mouse Model.
  • Jana Desloovere, P. Boon, R. Raedt
  • Biology, Psychology
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
  • 2021
TLDR
Results show that the chemogenetic therapeutic strategy with either clozapine or JHU37160 effectively suppresses spontaneous seizures in the IHKA mouse model, confirming JH U37160 as an effective DREADD ligand.
Characterization of DREADD receptor expression and function in rhesus macaques trained to discriminate ethanol
TLDR
These experiments highlight the NAc in mediating the interoceptive effects of ethanol, provide a framework for validation of chemogenetic tools in primates, and underscore the importance of robust within-subjects examination of DREADD expression for interpretation of behavioral findings.
Evidence in primates supporting the use of chemogenetics for the treatment of human refractory neuropsychiatric disorders.
[11C]deschloroclozapine is an improved PET radioligand for quantifying a human muscarinic DREADD expressed in monkey brain
  • Xuefeng Yan, S. Telu, M. Eldridge
  • Biology, Medicine
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2021
TLDR
PET was used to quantitatively and separately measure the signal from transfected receptors, endogenous receptors/targets, and non-displaceable binding in other brain regions to better understand this superiority of [11C]DCZ for imaging Designer Receptors Exclusively Activated by Designer Drugs (DREADDs).
Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice
TLDR
It is shown that intraperitoneal injections of commonly used doses of CNO alter sleep in wild-type male laboratory mice, and it is suggested that electrophysiological sleep assessment could serve as a sensitive tool to test the biological inertness of novel chemogenetic actuators.
Coordination chemogenetics for activation of GPCR-type glutamate receptors in brain tissue
TLDR
A chemogenetic method for direct activation of metabotropic glutamate receptor 1 (mGlu1), which plays essential roles in cerebellar functions in the brain, is developed, revealing that activation of endogenous mGLU1 is sufficient to evoke the critical cellular mechanism of synaptic plasticity, a basis of motor learning in the cerebellum.
Chemogenetic inactivation reveals the inhibitory control function of the prefronto-striatal pathway in the macaque brain
TLDR
These results show that the authors successfully suppressed pathway-selective neural activity in the macaque brain, and the resulting behavioral changes suggest that the LPFC-CdN pathway is involved in inhibitory control.
Modulating D1 rather than D2 receptor-expressing spiny-projection neurons corresponds to optimal antipsychotic effect
TLDR
D1- SPN activity is a more relevant therapeutic target than D2-SPN activity for the development of effective antipsychotics, and compounds that selectively target D1-SPNs are evaluated.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo
TLDR
DREADD agonist 21 (C21) (11-(1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine) is a potent and selective agonist at both excitatory and inhibitory DREADDs and has excellent bioavailability, pharmacokinetic properties, and brain penetrability.
Behavioral Effect of Chemogenetic Inhibition Is Directly Related to Receptor Transduction Levels in Rhesus Monkeys
TLDR
A significant relationship between the extent of DreadD transduction and the magnitude of behavioral deficit following administration of the DREADD actuator compound clozapine-N-oxide (CNO) is found.
Chemogenetics revealed: DREADD occupancy and activation via converted clozapine
TLDR
Radioligand receptor occupancy measurements and in vivo positron emission tomography are used to show that DREADDs expressed in the brain are not activated by the designer compound CNO (clozapine N-oxide), instead, they areactivated by the CNO metabolite clozapines, a drug with multiple endogenous targets.
Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics.
TLDR
An extensive pharmacokinetic study using subcutaneous administration of CNO in five adult rhesus monkeys suggests that CNO metabolism and distribution may interfere with reproducibility and interpretation of DREADD-related experiments in nonhuman primate experiments in NHPs and calls for a re-evaluation of the use.
The First Structure–Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs
TLDR
The first SAR studies of hM3Dq are conducted, which explored multiple regions of the scaffold represented by CNO, identified interesting SAR trends, and discovered several compounds that are very potent hM 3Dq agonists but do not activate the native human M3 receptor (hM3).
Ultrapotent chemogenetics for research and potential clinical applications
TLDR
A toolbox of modular ion channels and selective, ultrapotent agonists that can be used for targeted control of brain activity in rodent and primate models is developed.
The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice
TLDR
The present demonstration that CNO is converted to clozapine and exerts clozAPine-like behavioral effects in both mice and rats further emphasizes the need for appropriate control groups in studies employing DREADDs, and highlights the utility of the drug discrimination procedure as a tool with which to screen the off-target effects of novel DREADD agonists.
PET imaging-guided chemogenetic silencing reveals a critical role of primate rostromedial caudate in reward evaluation
TLDR
It is demonstrated that inactivating bilateral rmCD through activation of hM4Di produces a significant and reproducible loss of sensitivity to reward value in monkeys, indicating that the rmCD is involved in making normal judgments about the value of reward.
Acoustically targeted chemogenetics for the non-invasive control of neural circuits
TLDR
A cell-type-specific and non-invasive approach based on acoustically targeted chemogenetics that enables the modulation of neural circuits with spatiotemporal specificity and overcomes some of the key limitations associated with conventional brain therapies is reported.
...
1
2
3
4
5
...